|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||510.42 g·mol−1|
|3D model (JSmol)|
|NY (what is this?)|
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesity, but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.
- Kim MA, Yun H, Kwak H, Kim J, Lee J (2008). "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron. 64 (48): 10802–10809. doi:10.1016/j.tet.2008.09.057.
- Woods SC (November 2007). "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants. Suppl Endocannabinoid (11): 7–10. doi:10.1097/01720610-200711000-00005. PMID 18047036. S2CID 25472128.
- "Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
|Allosteric CBR ligands|